| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,302 |
2,889 |
$551.42 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
895 |
754 |
$164.54 |
| 99441 |
|
848 |
799 |
$0.00 |
| 81001 |
|
309 |
290 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
426 |
422 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
7,312 |
6,304 |
$0.00 |
| 3075F |
|
246 |
244 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,859 |
3,821 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
3,847 |
3,530 |
$0.00 |
| 82043 |
|
605 |
579 |
$0.00 |
| 85652 |
|
29 |
29 |
$0.00 |
| 3074F |
|
927 |
857 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,149 |
1,897 |
$0.00 |
| 84153 |
|
25 |
24 |
$0.00 |
| 86780 |
|
222 |
221 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
769 |
763 |
$0.00 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,174 |
1,095 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
334 |
329 |
$0.00 |
| 1220F |
|
313 |
311 |
$0.00 |
| 90686 |
|
206 |
206 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
999 |
989 |
$0.00 |
| 85027 |
|
936 |
907 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,480 |
1,463 |
$0.00 |
| 87522 |
Neg quan hep c or qual rna |
341 |
336 |
$0.00 |
| 1111F |
|
325 |
309 |
$0.00 |
| 82607 |
|
61 |
60 |
$0.00 |
| 83735 |
|
435 |
336 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
71 |
69 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
170 |
155 |
$0.00 |
| 82728 |
|
56 |
56 |
$0.00 |
| 3044F |
|
477 |
474 |
$0.00 |
| 3079F |
|
204 |
200 |
$0.00 |
| 87340 |
|
56 |
55 |
$0.00 |
| 86141 |
|
41 |
41 |
$0.00 |
| 97010 |
|
33 |
24 |
$0.00 |
| 90656 |
|
89 |
89 |
$0.00 |
| 82746 |
|
30 |
29 |
$0.00 |
| 83550 |
|
72 |
70 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
16 |
14 |
$0.00 |
| 3080F |
|
27 |
27 |
$0.00 |
| 3052F |
|
13 |
13 |
$0.00 |
| 99443 |
|
24 |
24 |
$0.00 |
| 80061 |
Lipid panel |
3,258 |
3,233 |
$0.00 |
| 82274 |
|
503 |
503 |
$0.00 |
| 84460 |
|
227 |
227 |
$0.00 |
| 3077F |
|
259 |
240 |
$0.00 |
| 85610 |
|
447 |
337 |
$0.00 |
| 86703 |
|
810 |
808 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,825 |
2,348 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
334 |
329 |
$0.00 |
| 1033F |
|
65 |
64 |
$0.00 |
| 82540 |
|
605 |
579 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
422 |
212 |
$0.00 |
| 3078F |
|
1,220 |
1,131 |
$0.00 |
| 81003 |
|
89 |
81 |
$0.00 |
| 84450 |
|
155 |
155 |
$0.00 |
| 3046F |
|
33 |
33 |
$0.00 |
| 83540 |
|
114 |
111 |
$0.00 |
| 80074 |
|
12 |
12 |
$0.00 |
| 99442 |
|
273 |
268 |
$0.00 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
137 |
137 |
$0.00 |
| 77062 |
|
68 |
68 |
$0.00 |
| 82570 |
|
28 |
26 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
33 |
33 |
$0.00 |
| 83970 |
|
12 |
12 |
$0.00 |
| 84439 |
|
12 |
12 |
$0.00 |
| 3051F |
|
24 |
24 |
$0.00 |
| 84100 |
|
41 |
27 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
19 |
18 |
$0.00 |
| 97161 |
|
12 |
12 |
$0.00 |